Safety of intradermal administration of monosodium urate crystals as a carrier of idiotype cancer vaccine

Safety of intradermal administration of monosodium urate crystals as a carrier of idiotype cancer vaccine - Safety of intradermal administration of monosodium urate crystals

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001624

Enrollment

Registered

2009-01-07

Start date

2007-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple myeloma

Interventions

Intradermal administration of monosodium urate crystals 2.0 mcg of monosodium urate crystals per administration 20 mcg of monosodium urate crystals per administration 200 mcg of monosodium urate cr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy volunteer under aged 60 who agreed to participate in writing

Exclusion criteria

Exclusion criteria: 1) Adolecents having major organ injury indicated by elevated level of serum creatinine, total bilirubin or ALT , or having symptomatic congestive heart failure 2) Patients suffering from gout 3) Patients with any of active autoimmune disease 4) Patients with any of active infectious disease 5) Women on (possible) pregnancy or lactation 6) Adolecents judged inadequate by doctor in charge of the patient or the study

Design outcomes

Primary

Measure	Time frame
Safetiness during three weeks following the administration of monosodium urate crystals	—

Secondary

Measure	Time frame
Serum level of inflammatory cytokines Decndritic cell count in the peripheral blood	—

Countries

Japan

Contacts

Public ContactMitsuaki Tanaka

National Hospital Organization Awara Hospital Department of Pharmacy

nhoawara-secretary@umin.ac.jp0776-79-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026